Eterna Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ERNA Nasdaq 2836 eternatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eterna Therapeutics Inc.

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models - Dec 3rd, 2024 1:30 pm
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program - Nov 25th, 2024 1:30 pm
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - Nov 14th, 2024 1:30 pm
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - Oct 30th, 2024 12:30 pm
Eterna, Factor announce license, collaboration agreement - Oct 18th, 2024 12:06 pm
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - Oct 17th, 2024 12:00 pm
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases - May 10th, 2024 12:00 pm
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - May 8th, 2024 1:31 pm
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus - May 7th, 2024 12:00 pm
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors - Feb 20th, 2024 1:30 pm
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) - Jan 3rd, 2024 9:15 pm
Eterna Therapeutics Appoints Sanjeev Luther as President and CEO - Dec 21st, 2023 4:18 pm
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer - Dec 20th, 2023 9:15 pm
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing - Dec 14th, 2023 11:56 pm